The aim – to study the effect of adherence to treatment in patients with obesity in combination with NAFLD on the effectiveness of treatment of NAFLD
Materials that methods. 93 patients with obesity 1,2,3 degrees (BMI = 30-44.9 kg \ m2) in combination with NAFLD were examined. The patients were divided into two groups by randomization. They were offered a comprehensive weight loss program consisting of 5 visits over 12 weeks. The comprehensive weight loss program included: a reduction in the energy diet by 500 kcal from physiological daily energy expenditure and a moderate physical activity of 150-200 min per week. The patients of the first group adhered to the comprehensive weight loss program and received pioglitazone 15 mg / day. Patients of the second group adhered only to comprehensive weight loss program. We studied adherence to treatment in two groups of patients using self-report questionnare. The survey on Obesity WGO recommendations was also conducted. All patients underwent anthropometric measurements, laboratory and instrumental examination.
Results. The comparative analysis revealed that patients with obesity and NAFLD in group 1, who followed a comprehensive weight loss program and received pioglitazone at a daily dose of 15 mg, had significantly better adherence rates (70.4%) (p <0, 05) compared with patients in Group 2 (59.6%) who followed only a comprehensive weight loss program. It was found that in patients of group 1, controlled attenuation parameter had a strong negative correlation with the level of adherence to treatment (r = -0,71), compared with patients in group 2, where there was an medium negative correlation (r = -0.56). It was found that the level of adherence to treatment had a medium negative correlation with the number of previous attempts to lose weight (r = -0.52) and the duration of obesity (r = -0.49).
Conclusions. Patients who received pioglitazone 15 mg / day in addition to comprehensive weight loss program were likely to have better adherence rates and, as a consequence, a more significant decrease in steatosis. It is revealed that the level of adherence to treatment depends on the number of previous attempts to lose weight and the duration of obesity.
NCD Risk Factor Collaboration (NCD-RisC). (2017). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet, 390, 2627–42.
Pais R., Barritt A.S. 4th, Calmus Y., Scatton O., Runge T., Lebray P., Poynard T., Ratziu V., Conti F. (2016). NAFLD and liver transplantation: Current burden and expected challenges. J. Hepatol., 2(65), 1245-57.
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease 2016. (2016). J. Hepatol., 64 (6), 1388-402. https://doi.org/10.1016/j.jhep.2015.11.004
Agarwal А., Ioannidis J. P. A. (2019). PREDIMED trial of Mediterranean diet: retracted, republished, still trusted? BMJ, 364, l341 doi: 10.1136/bmj.l341 (Published 7 February 2019)
Filozof C., Goldstein B.J., Williams R.N., Sanyal A. (2015). Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs, 75(12), 1373-92, doi: 10.1007/s40265-015-0437-3.
Schutz D. D., Busetto L., Dicker D., Farpour-Lambert N., Pryke R., Toplak H., Widmer D., Yumuk V., Schutz Y. (2019). European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes. Facts, 12, 40–66 .
Simpson S.A., McNamara R., Shaw C., Kelson M., Moriarty Y., Randell E., Cohen D., Alam M.F., Copeland L., Duncan D., Espinasse A., Gillespie D., Hill A., Owen-Jones E., Tapper K., Townson J., Williams S., Hood K. (2015). A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults. Health Technol. Assess., 19(50), doi: 10.3310/hta19500.
Sansone R.A., Bohinc R.J., Wiederman M.W. (2015). Body mass index and self-reported compliance with general health care. South. Med. J.,108, 79.
Miller B.M.L., Brennan L. (2015). Measuring and reporting attrition from obesity treatment programs: a call to action!. Obes. Res. Clin. Pract., 9, 187–202.
Burgess E., Hassmén P., Pumpa K.L. (2017). Determinants of adherence to lifestyle intervention in adults with obesity: a systematic review. Clin. Obes., 7(3), 123-135. doi: 10.1111/cob.12183.
Hadžiabdic´ M.O., Mucalo I., Hrabac P., Matić T., Rahelić D., Božikov V. (2015). Factors predictive of drop-out and weight loss success in weight management of obese patients. J. Hum. Nutr. Diet, 28 Suppl 2, 24–32, doi: 10.1186/s12966-015-0258-5.
Kovac Blaz M., Svab I. (2015). A multidisciplinary approach to treating obesity in a community health centre. Zdr.Varst., 54(4), 252–258, doi: 10.1515/sjph-2015-0033.
Sansone R.A., Bohinc R.J., Wiederman M.W. (2015). Body mass index and self-reported compliance with general health care. South. Med. J., 108, 79–81.
Burgess Е., Hassmén P., Welvaert M., Pumpa K.L. (2017). Behavioural treatment strategies improve adherence to lifestyle intervention programmes in adults with obesity: a systematic review and meta-analysis. Clin. Obes., 7(2), 105-114, doi: 10.1111/cob.12180.
Shypulin V.P., Parunyan L.M., Tishhenko V.V., Kolyada О.K., Ponomarov O.M., Melnyk N.G. (2019). Effectiveness of treatment with pioglitazone in patients with non-alcoholic fatty liver disease and concomitant metabolic syndrome depending on presence rs 1801282 (Pro12Ala) polymorphism in gene PPAR-γ. Med. Sci. of Ukraine (MSU), 15(1-2), 25-33. https://doi.org/10.32345/2664-4738.1-2.2019.04
Mathus-Vliegen L., Toouli J., Fried M., Khan A.G., Garisch J., Hunt R., Fedail S., Štimac D., Lemair T., Krabshuis J., Kaufmann P., Roberts E., Riccardi G. World Gastroenterology Organization. (2012). World Gastroenterology Organisation global guidelines on obesity. J. Clin. Gastroenterol., 46 (7), 555-61. doi: 10.1097/MCG.0b013e318259bd04
Marunchyn N.A., Dynnyk O.B., Kovalerenko L.S. (2017). Zastosuvannja pryncypu mul'typarametrychnogo ul'trazvuku dlja diagnostyky nealkogol'noji zhyrovoji hvoroby pechinky u pacijentiv z cukrovym diabetom 2 typu. Mizhnarodnyj endokrynologichnyj zhurnal, 13(2), 87 – 92.
Morisky D.E., Green L.W., Levine D.M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care, 24, 67–74.
ACTOS® Product Monograph (pioglitazone hydrochloride) https://www.takeda.com/siteassets/en-ca/home/what-we-do/our-medicines/product-monographs/actos/actos-pm-18jan2018-clean_en.pdf
Lee J., Cho Y.K., Kang Y.M., Kim H.S., Jung C.H., Kim H.-K., Park J.-Y., Lee W. J. (2019). The Impact of NAFLD and Waist Circumference Changes on Diabetes Development in Prediabetes Subjects. Sci. Rep., 9, 17258.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.